A citation-based method for searching scientific literature

Susan A Sabatino, Ellen P McCarthy, Russell S Phillips, Risa B Burns. Cancer Detect Prev 2007
Times Cited: 71







List of co-cited articles
503 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Projecting individualized probabilities of developing breast cancer for white females who are being examined annually.
M H Gail, L A Brinton, D P Byar, D K Corle, S B Green, C Schairer, J J Mulvihill. J Natl Cancer Inst 1989
29

Factors affecting breast cancer risk reduction practices among California physicians.
Celia Patricia Kaplan, Jennifer S Haas, Eliseo J Pérez-Stable, Genevieve Des Jarlais, Steven E Gregorich. Prev Med 2005
68
27

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.
B Fisher, J P Costantino, D L Wickerham, C K Redmond, M Kavanah, W M Cronin, V Vogel, A Robidoux, N Dimitrov, J Atkins,[...]. J Natl Cancer Inst 1998
25

A breast cancer prediction model incorporating familial and personal risk factors.
Jonathan Tyrer, Stephen W Duffy, Jack Cuzick. Stat Med 2004
644
22

Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer.
Victor G Vogel, Joseph P Costantino, D Lawrence Wickerham, Walter M Cronin, Reena S Cecchini, James N Atkins, Therese B Bevers, Louis Fehrenbacher, Eduardo R Pajon, James L Wade,[...]. Cancer Prev Res (Phila) 2010
385
21

Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.
Victor G Vogel, Joseph P Costantino, D Lawrence Wickerham, Walter M Cronin, Reena S Cecchini, James N Atkins, Therese B Bevers, Louis Fehrenbacher, Eduardo R Pajon, James L Wade,[...]. JAMA 2006
21

Validation studies for models projecting the risk of invasive and total breast cancer incidence.
J P Costantino, M H Gail, D Pee, S Anderson, C K Redmond, J Benichou, H S Wieand. J Natl Cancer Inst 1999
484
21

Exemestane for breast-cancer prevention in postmenopausal women.
Paul E Goss, James N Ingle, José E Alés-Martínez, Angela M Cheung, Rowan T Chlebowski, Jean Wactawski-Wende, Anne McTiernan, John Robbins, Karen C Johnson, Lisa W Martin,[...]. N Engl J Med 2011
544
21

Estimates of the number of US women who could benefit from tamoxifen for breast cancer chemoprevention.
Andrew N Freedman, Barry I Graubard, Sowmya R Rao, Worta McCaskill-Stevens, Rachel Ballard-Barbash, Mitchell H Gail. J Natl Cancer Inst 2003
175
18

Diffusion of breast cancer risk assessment in primary care.
Carmen E Guerra, Melani Sherman, Katrina Armstrong. J Am Board Fam Med 2009
32
40

Benefit/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older.
Andrew N Freedman, Binbing Yu, Mitchell H Gail, Joseph P Costantino, Barry I Graubard, Victor G Vogel, Garnet L Anderson, Worta McCaskill-Stevens. J Clin Oncol 2011
122
18


Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial.
Jack Cuzick, Ivana Sestak, John F Forbes, Mitch Dowsett, Jill Knox, Simon Cawthorn, Christobel Saunders, Nicola Roche, Robert E Mansel, Gunter von Minckwitz,[...]. Lancet 2014
333
18

Factors affecting uptake and adherence to breast cancer chemoprevention: a systematic review and meta-analysis.
S G Smith, I Sestak, A Forster, A Partridge, L Side, M S Wolf, R Horne, J Wardle, J Cuzick. Ann Oncol 2016
122
18

Prevalence of tamoxifen use for breast cancer chemoprevention among U.S. women.
Erika A Waters, Kathleen A Cronin, Barry I Graubard, Paul K Han, Andrew N Freedman. Cancer Epidemiol Biomarkers Prev 2010
108
16

Use of the Gail model and breast cancer preventive therapy among three primary care specialties.
Jennifer Corbelli, Sonya Borrero, Rachel Bonnema, Megan McNamara, Kevin Kraemer, Doris Rubio, Irina Karpov, Melissa McNeil. J Womens Health (Larchmt) 2014
30
40

Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.
Bernard Fisher, Joseph P Costantino, D Lawrence Wickerham, Reena S Cecchini, Walter M Cronin, Andre Robidoux, Therese B Bevers, Maureen T Kavanah, James N Atkins, Richard G Margolese,[...]. J Natl Cancer Inst 2005
825
15

Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline.
Kala Visvanathan, Patricia Hurley, Elissa Bantug, Powel Brown, Nananda F Col, Jack Cuzick, Nancy E Davidson, Andrea Decensi, Carol Fabian, Leslie Ford,[...]. J Clin Oncol 2013
195
15

Patient reluctance toward tamoxifen use for breast cancer primary prevention.
E R Port, L L Montgomery, A S Heerdt, P I Borgen. Ann Surg Oncol 2001
155
14

Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene.
Silvana Martino, Jane A Cauley, Elizabeth Barrett-Connor, Trevor J Powles, John Mershon, Damon Disch, Roberta J Secrest, Steven R Cummings. J Natl Cancer Inst 2004
430
14

Awareness and utilization of BRCA1/2 testing among U.S. primary care physicians.
Cecelia A Bellcross, Katherine Kolor, Katrina A B Goddard, Ralph J Coates, Michele Reyes, Muin J Khoury. Am J Prev Med 2011
109
14

Women's interest in taking tamoxifen and raloxifene for breast cancer prevention: response to a tailored decision aid.
Angela Fagerlin, Amanda J Dillard, Dylan M Smith, Brian J Zikmund-Fisher, Rosemarie Pitsch, Jennifer B McClure, Sarah Greene, Sharon Hensley Alford, Vijayan Nair, Daniel F Hayes,[...]. Breast Cancer Res Treat 2011
56
17

Decision-making about tamoxifen in women at high risk for breast cancer: clinical and psychological factors.
Sharon L Bober, Lizbeth A Hoke, Rosemary B Duda, Meredith M Regan, Nadine M Tung. J Clin Oncol 2004
106
14

Using clinical factors and mammographic breast density to estimate breast cancer risk: development and validation of a new predictive model.
Jeffrey A Tice, Steven R Cummings, Rebecca Smith-Bindman, Laura Ichikawa, William E Barlow, Karla Kerlikowske. Ann Intern Med 2008
328
14

Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial.
Jack Cuzick, Ivana Sestak, Simon Cawthorn, Hisham Hamed, Kaija Holli, Anthony Howell, John F Forbes. Lancet Oncol 2015
217
14

American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography.
Debbie Saslow, Carla Boetes, Wylie Burke, Steven Harms, Martin O Leach, Constance D Lehman, Elizabeth Morris, Etta Pisano, Mitchell Schnall, Stephen Sener,[...]. CA Cancer J Clin 2007
12

Genetic assessment of breast cancer risk in primary care practice.
Wylie Burke, Julie Culver, Linda Pinsky, Sarah Hall, Susan E Reynolds, Yutaka Yasui, Nancy Press. Am J Med Genet A 2009
49
18


Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial.
Trevor J Powles, Sue Ashley, Alwynne Tidy, Ian E Smith, Mitch Dowsett. J Natl Cancer Inst 2007
262
12

Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data.
Jack Cuzick, Ivana Sestak, Bernardo Bonanni, Joseph P Costantino, Steve Cummings, Andrea DeCensi, Mitch Dowsett, John F Forbes, Leslie Ford, Andrea Z LaCroix,[...]. Lancet 2013
256
12


Preferences of Women Evaluating Risks of Tamoxifen (POWER) study of preferences for tamoxifen for breast cancer risk reduction.
Joy Melnikow, Debora Paterniti, Rahman Azari, Christina Kuenneth, Stephen Birch, Miriam Kuppermann, James Nuovo, Janet Keyzer, Stuart Henderson. Cancer 2005
59
13

Projecting individualized absolute invasive breast cancer risk in African American women.
Mitchell H Gail, Joseph P Costantino, David Pee, Melissa Bondy, Lisa Newman, Mano Selvan, Garnet L Anderson, Kathleen E Malone, Polly A Marchbanks, Worta McCaskill-Stevens,[...]. J Natl Cancer Inst 2007
182
11

The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation.
S R Cummings, S Eckert, K A Krueger, D Grady, T J Powles, J A Cauley, L Norton, T Nickelsen, N H Bjarnason, M Morrow,[...]. JAMA 1999
11

Women's decisions regarding tamoxifen for breast cancer prevention: responses to a tailored decision aid.
Angela Fagerlin, Brian J Zikmund-Fisher, Vijayan Nair, Holly A Derry, Jennifer B McClure, Sarah Greene, Azadeh Stark, Sharon Hensley Alford, Paula Lantz, Daniel F Hayes,[...]. Breast Cancer Res Treat 2010
65
12

Implementation in a large health system of a program to identify women at high risk for breast cancer.
William L Owens, Thomas J Gallagher, Michael J Kincheloe, Victoria L Ruetten. J Oncol Pract 2011
28
28

Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy.
Umberto Veronesi, Patrick Maisonneuve, Nicole Rotmensz, Bernardo Bonanni, Peter Boyle, Giuseppe Viale, Alberto Costa, Virgilio Sacchini, Roberto Travaglini, Giuseppe D'Aiuto,[...]. J Natl Cancer Inst 2007
147
11

The BOADICEA model of genetic susceptibility to breast and ovarian cancer.
A C Antoniou, P P D Pharoah, P Smith, D F Easton. Br J Cancer 2004
280
9

Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.
Stephanie R Land, D Lawrence Wickerham, Joseph P Costantino, Marcie W Ritter, Victor G Vogel, Myoungkeun Lee, Eduardo R Pajon, James L Wade, Shaker Dakhil, James B Lockhart,[...]. JAMA 2006
165
9

Prescription of tamoxifen for breast cancer prevention by primary care physicians.
Katrina Armstrong, D Alex Quistberg, Ellyn Micco, Susan Domchek, Carmen Guerra. Arch Intern Med 2006
53
13

Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer.
M H Gail, J P Costantino, J Bryant, R Croyle, L Freedman, K Helzlsouer, V Vogel. J Natl Cancer Inst 1999
462
9

American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction.
Kala Visvanathan, Rowan T Chlebowski, Patricia Hurley, Nananda F Col, Mary Ropka, Deborah Collyar, Monica Morrow, Carolyn Runowicz, Kathleen I Pritchard, Karen Hagerty,[...]. J Clin Oncol 2009
196
9

Reported referral for genetic counseling or BRCA 1/2 testing among United States physicians: a vignette-based study.
Katrina F Trivers, Laura-Mae Baldwin, Jacqueline W Miller, Barbara Matthews, C Holly A Andrilla, Denise M Lishner, Barbara A Goff. Cancer 2011
76
9


"Why take it if you don't have anything?" breast cancer risk perceptions and prevention choices at a public hospital.
Talya Salant, Pamela S Ganschow, Olufunmilayo I Olopade, Diane S Lauderdale. J Gen Intern Med 2006
50
14

Regulatory approval of cancer risk-reducing (chemopreventive) drugs: moving what we have learned into the clinic.
Frank L Meyskens, Gregory A Curt, Dean E Brenner, Gary Gordon, Ronald B Herberman, Olivera Finn, Gary J Kelloff, Samir N Khleif, Caroline C Sigman, Eva Szabo. Cancer Prev Res (Phila) 2011
37
18

Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial.
Jack Cuzick, John F Forbes, Ivana Sestak, Simon Cawthorn, Hisham Hamed, Kaija Holli, Anthony Howell. J Natl Cancer Inst 2007
354
9

Use of tamoxifen and raloxifene for breast cancer chemoprevention in 2010.
Erika A Waters, Timothy S McNeel, Worta McCaskill Stevens, Andrew N Freedman. Breast Cancer Res Treat 2012
102
9


First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial.
J Cuzick, J Forbes, R Edwards, M Baum, S Cawthorn, A Coates, A Hamed, A Howell, T Powles. Lancet 2002
518
9


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.